| Bioactivity | Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research[1]. |
| Target | Plasma kallikrein |
| Invitro | Plasma kallikrein-IN-3 (example 13, 1 nM-100 μM, 1 h) inhibits plasma kallikrein activity with an IC50 value of 0.15 μM[1]. |
| Name | Plasma kallikrein-IN-3 |
| CAS | 1357950-47-0 |
| Formula | C20H23N5O2 |
| Molar Mass | 365.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Brandl Trixi, et al. Preparation of N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein. Patent WO2012017020. |
Plasma kallikrein-IN-3
CAS: 1357950-47-0 F: C20H23N5O2 W: 365.43
Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for heredit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.